Payment overview · 2025
General Payments
$84.38
3 reported records · 3 companies
Healthcare provider profile · identity verified
Michael U Igbokwe, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MORRISTOWN, TN · NPI 1407209562
Verified facts
What the public records show
CMS Open Payments records show Michael U Igbokwe, FNP-BC received $84.38 in general payments during 2025 across 3 reported records.
Inspire Medical Systems, Inc. accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $33.33 | 39.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.77 | 36.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.28 | 24.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $84.38 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $33.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.77 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 504 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 499 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 457 | 111 |
| Furosemide | Furosemide | 363 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 310 | 70 |
| Sertraline Hcl | Sertraline Hcl | 269 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 250 | 49 |
| Eliquis | Apixaban | 239 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 234 | 62 |
| Dexamethasone | Dexamethasone | 219 | 158 |
| Omeprazole | Omeprazole | 212 | 40 |
| Lisinopril | Lisinopril | 211 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 209 | 54 |
| Donepezil Hcl | Donepezil Hcl | 200 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 200 | 44 |
| Potassium Chloride | Potassium Chloride | 198 | 49 |
| Cefdinir | Cefdinir | 189 | 152 |
| Buspirone Hcl | Buspirone Hcl | 188 | 47 |
| Losartan Potassium | Losartan Potassium | 176 | 37 |
| Trazodone Hcl | Trazodone Hcl | 166 | 44 |
| Mirtazapine | Mirtazapine | 152 | 36 |
| Memantine Hcl | Memantine Hcl | 137 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 35 |
| Montelukast Sodium | Montelukast Sodium | 134 | 34 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 133 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 116 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 31 |
| Metformin Hcl | Metformin Hcl | 104 | 31 |
| Celecoxib | Celecoxib | 101 | 42 |
| Azithromycin | Azithromycin | 99 | 89 |
| Famotidine | Famotidine | 99 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 25 |
| Fluconazole | Fluconazole | 93 | 56 |
| Finasteride | Finasteride | 92 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 21 |
| Simvastatin | Simvastatin | 88 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 42 |
| Cephalexin | Cephalexin | 78 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 12 |
| Tramadol Hcl | Tramadol Hcl | 77 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 63 |
| Alprazolam | Alprazolam | 75 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 15 |
| Lovastatin | Lovastatin | 70 | suppressed |
| Carvedilol | Carvedilol | 67 | 14 |
| Allopurinol | Allopurinol | 66 | 17 |
| Clonazepam | Clonazepam | 66 | suppressed |
| Pregabalin | Pregabalin | 60 | 12 |
| Ezetimibe | Ezetimibe | 59 | 16 |
| Levetiracetam | Levetiracetam | 58 | suppressed |
| Spironolactone | Spironolactone | 57 | 16 |
| Alendronate Sodium | Alendronate Sodium | 56 | 12 |
| Atenolol | Atenolol | 56 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 45 |
| Glipizide Er | Glipizide | 55 | 19 |
| Lorazepam | Lorazepam | 54 | 19 |
| Farxiga | Dapagliflozin Propanediol | 53 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | suppressed |
| Latanoprost | Latanoprost | 52 | 11 |
| Mounjaro | Tirzepatide | 52 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 15 |
| Risperidone | Risperidone | 49 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 25 |
| Benazepril Hcl | Benazepril Hcl | 47 | 11 |
| Divalproex Sodium | Divalproex Sodium | 46 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 45 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 42 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 11 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Prednisone | Prednisone | 38 | 11 |
| Sucralfate | Sucralfate | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | 17 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Bumetanide | Bumetanide | 36 | 11 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 34 | suppressed |
| Methocarbamol | Methocarbamol | 33 | 15 |
| Mupirocin | Mupirocin | 33 | 25 |
| Primidone | Primidone | 32 | suppressed |
| Hydroxyurea | Hydroxyurea | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Nystatin | Nystatin | 30 | 21 |
| Temazepam | Temazepam | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 27 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 11 |
| Diazepam | Diazepam | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 20 |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 22 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | 14 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Galantamine Er | Galantamine Hbr | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Ondansetron Odt | Ondansetron | 17 | 15 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Linezolid | Linezolid | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 11 |
| Qulipta | Atogepant | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $84.38 · 3 records | Inspire Medical Systems, Inc. | INGREZZA, INSPIRE, Ozempic, Rybelsus | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error